Suppr超能文献

生长激素与心力衰竭:对患者分层、预后及精准医学的影响

Growth Hormone and Heart Failure: Implications for Patient Stratification, Prognosis, and Precision Medicine.

作者信息

Theodorakis Nikolaos, Kreouzi Magdalini, Hitas Christos, Anagnostou Dimitrios, Nikolaou Maria

机构信息

NT-CardioMetabolics, Clinic for Metabolism and Athletic Performance, 17564 Palaio Faliro, Greece.

School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

出版信息

Diagnostics (Basel). 2024 Dec 16;14(24):2831. doi: 10.3390/diagnostics14242831.

Abstract

Heart failure (HF) remains a major cause of morbidity and mortality worldwide. While standard treatments primarily target neurohormonal pathways, emerging evidence highlights the significant role of hormonal deficiencies, such as impaired growth hormone (GH) signaling, in HF progression and outcomes. GH is crucial for cardiovascular and skeletal muscle function, and its deficiency has been associated with worse prognosis. This review synthesizes recent findings from randomized controlled trials (RCTs) to explore how GH can contribute to personalized care and improve patient stratification in HF. A comprehensive literature review was conducted using PubMed up to 10 October 2024. Search terms included "growth hormone" combined with "heart failure", "HFrEF", "HFpEF", and "HFmrEF." Only placebo-controlled RCTs published in English and involving human subjects were considered. Data on study design, participant characteristics, GH dosing, and key clinical outcomes were systematically extracted and analyzed. Several trials demonstrated that GH therapy can transiently improve left ventricular ejection fraction (LVEF), exercise capacity, and reduce inflammatory markers. For example, one study has reported an increase in LVEF from 32 ± 3.8% to 43.8 ± 4.6% ( = 0.002), following three months of GH therapy in post-MI HF patients. However, benefits diminished after discontinuation. Additional studies have observed sustained improvements in peak oxygen consumption and LVEF over four years, with an additional trend towards hard endpoint improvement. Conversely, some studies showed no significant impact on cardiac function, highlighting heterogeneity in outcomes. As a result, GH therapy holds promise for improving cardiac and functional parameters in HF patients, but evidence remains mixed. Larger, long-term RCTs are needed to confirm its efficacy and safety. Precision medicine approaches and biomarker-driven strategies may optimize patient outcomes and guide clinical practice.

摘要

心力衰竭(HF)仍然是全球发病和死亡的主要原因。虽然标准治疗主要针对神经激素途径,但新出现的证据凸显了激素缺乏(如生长激素(GH)信号受损)在HF进展和预后中的重要作用。GH对心血管和骨骼肌功能至关重要,其缺乏与更差的预后相关。本综述综合了随机对照试验(RCT)的最新发现,以探讨GH如何有助于HF的个性化护理并改善患者分层。使用截至2024年10月10日的PubMed进行了全面的文献综述。检索词包括“生长激素”与“心力衰竭”、“射血分数降低的心力衰竭(HFrEF)”、“射血分数保留的心力衰竭(HFpEF)”和“射血分数中间值的心力衰竭(HFmrEF)”。仅考虑以英文发表且涉及人类受试者的安慰剂对照RCT。系统地提取并分析了关于研究设计、参与者特征、GH剂量和关键临床结局的数据。多项试验表明,GH治疗可短暂改善左心室射血分数(LVEF)、运动能力并降低炎症标志物。例如,一项研究报告称,心肌梗死后HF患者接受三个月的GH治疗后,LVEF从32±3.8%增加到43.8±4.6%( = 0.002)。然而,停药后益处消失。其他研究观察到四年内峰值耗氧量和LVEF持续改善,还有硬终点改善的额外趋势。相反,一些研究显示对心脏功能无显著影响,突出了结局的异质性。因此,GH治疗有望改善HF患者的心脏和功能参数,但证据仍然不一。需要更大规模、长期的RCT来证实其疗效和安全性。精准医学方法和生物标志物驱动的策略可能会优化患者结局并指导临床实践。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e19d/11675863/c6ecb912daf8/diagnostics-14-02831-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验